Neostigmine Versus Sugammadex on Renal Functions

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

December 31, 2023

Conditions
SugammadexNeostigmine
Interventions
DRUG

Neostigmine

a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium

DRUG

Sugammadex

2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium

Trial Locations (1)

32513

Menoufia University Hospitals, Shibīn al Kawm

All Listed Sponsors
lead

Menoufia University

OTHER